Amicus Therapeutics Inc (FOLD)
9.485
-0.10
(-1.09%)
USD |
NASDAQ |
Nov 21, 16:00
9.485
0.00 (0.00%)
After-Hours: 20:00
Amicus Therapeutics Enterprise Value: 3.005B for Nov. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2024 | 3.005B |
| November 19, 2024 | 2.984B |
| November 18, 2024 | 3.026B |
| November 15, 2024 | 3.032B |
| November 14, 2024 | 3.155B |
| November 13, 2024 | 3.238B |
| November 12, 2024 | 3.274B |
| November 11, 2024 | 3.334B |
| November 08, 2024 | 3.424B |
| November 07, 2024 | 3.421B |
| November 06, 2024 | 3.498B |
| November 05, 2024 | 3.648B |
| November 04, 2024 | 3.525B |
| November 01, 2024 | 3.567B |
| October 31, 2024 | 3.552B |
| October 30, 2024 | 3.600B |
| October 29, 2024 | 3.573B |
| October 28, 2024 | 3.582B |
| October 25, 2024 | 3.633B |
| October 24, 2024 | 3.652B |
| October 23, 2024 | 3.545B |
| October 22, 2024 | 3.685B |
| October 21, 2024 | 3.727B |
| October 18, 2024 | 3.694B |
| October 17, 2024 | 3.715B |
| Date | Value |
|---|---|
| October 16, 2024 | 3.276B |
| October 15, 2024 | 3.219B |
| October 14, 2024 | 3.252B |
| October 11, 2024 | 3.276B |
| October 10, 2024 | 3.142B |
| October 09, 2024 | 3.174B |
| October 08, 2024 | 3.139B |
| October 07, 2024 | 3.192B |
| October 04, 2024 | 3.306B |
| October 03, 2024 | 3.294B |
| October 02, 2024 | 3.303B |
| October 01, 2024 | 3.324B |
| September 30, 2024 | 3.330B |
| September 27, 2024 | 3.305B |
| September 26, 2024 | 3.308B |
| September 25, 2024 | 3.356B |
| September 24, 2024 | 3.457B |
| September 23, 2024 | 3.457B |
| September 20, 2024 | 3.477B |
| September 19, 2024 | 3.391B |
| September 18, 2024 | 3.365B |
| September 17, 2024 | 3.451B |
| September 16, 2024 | 3.409B |
| September 13, 2024 | 3.480B |
| September 12, 2024 | 3.474B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.402B
Minimum
Mar 12 2020
6.366B
Maximum
Dec 22 2020
3.248B
Average
3.196B
Median
Enterprise Value Benchmarks
| Tonix Pharmaceuticals Holding Corp | 15.27M |
| Alnylam Pharmaceuticals Inc | 30.33B |
| Ionis Pharmaceuticals Inc | 4.385B |
| Arbutus Biopharma Corp | 524.06M |
| Krystal Biotech Inc | 4.534B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.729M |
| Revenue (Quarterly) | 141.52M |
| Total Expenses (Quarterly) | 116.72M |
| EPS Diluted (Quarterly) | -0.02 |
| Gross Profit Margin (Quarterly) | 90.62% |
| Profit Margin (Quarterly) | -4.75% |
| Earnings Yield | -3.58% |
| Operating Earnings Yield | 0.50% |
| Normalized Earnings Yield | -2.947 |